As you may know, I have accepted an offer to join the talented and diverse team of scientific and medical professionals as a writer and biomedical analyst at Chimera Research Group. You can find more information about my transition here, and learn about what Chimera has to offer on the group's website. Stay tuned for an exciting and newsflow packed start to 2012 from Chimera as we ramp up our efforts and expand the services available to our members. There are several ways to join Chimera, including up to two weeks risk-free access to the complete website, archives, databases, and other member features.
For now, all of the information assembled on BiotechDueDiligence remains freely available to all. My various posts here on BDD give you a sense of the breadth and depth of coverage I provide. I will be initiating coverage for Chimera on a number of the stocks featured on BDD, so stay tuned for that information and more in-depth feature posts on these companies, their stocks, and important catalysts. Keep reading below for a preview of the posts I've already written for Chimera.
For now, all of the information assembled on BiotechDueDiligence remains freely available to all. My various posts here on BDD give you a sense of the breadth and depth of coverage I provide. I will be initiating coverage for Chimera on a number of the stocks featured on BDD, so stay tuned for that information and more in-depth feature posts on these companies, their stocks, and important catalysts. Keep reading below for a preview of the posts I've already written for Chimera.
SPPI: Generic Fusilev fears sparks selloff
(Click to access full text)
Publication of a Paragraph IV challenge for Fusilev's patent sent Spectrum Pharma shares tumbling. I explained the Paragraph IV process, evaluated the strength of SPPI's patent and Orphan Drug exclusivity protections, and summarized whether this sell-off was justified.
BPAX: Picking up the pieces
(Click to access full text)
We all know by now that the phase 3 efficacy trials for BioSante's LibiGel product failed, sending shares down 80%. I'm sure you're also inundated with bull and bear cases for trading this stock going forward. I thoroughly examined every asset BPAX has left without bias, such as its cancer vaccine portfolio and male testosterone gel with an upcoming PDUFA date with Teva.
AIS: Lies, Damn Lies, and Statistics
(Click to access full text)
My first provactive piece - I took a deep dive into the data and statistical analyses for Antares' Anturol overactive bladder gel product and several FDA approved competing products. What I found was apparent improprieties in data reported by AIS management that should be very concerning for former, current, or potential AIS shareholders.
Interested in reading these complete articles and many more from the other talented Chimera Research Group writers? Click here to learn about the benefits of membership and how to get 14 days free access to these posts and everything else Chimera offers.
(Click to access full text)
Publication of a Paragraph IV challenge for Fusilev's patent sent Spectrum Pharma shares tumbling. I explained the Paragraph IV process, evaluated the strength of SPPI's patent and Orphan Drug exclusivity protections, and summarized whether this sell-off was justified.
BPAX: Picking up the pieces
(Click to access full text)
We all know by now that the phase 3 efficacy trials for BioSante's LibiGel product failed, sending shares down 80%. I'm sure you're also inundated with bull and bear cases for trading this stock going forward. I thoroughly examined every asset BPAX has left without bias, such as its cancer vaccine portfolio and male testosterone gel with an upcoming PDUFA date with Teva.
AIS: Lies, Damn Lies, and Statistics
(Click to access full text)
My first provactive piece - I took a deep dive into the data and statistical analyses for Antares' Anturol overactive bladder gel product and several FDA approved competing products. What I found was apparent improprieties in data reported by AIS management that should be very concerning for former, current, or potential AIS shareholders.
Interested in reading these complete articles and many more from the other talented Chimera Research Group writers? Click here to learn about the benefits of membership and how to get 14 days free access to these posts and everything else Chimera offers.
RSS Feed
